209 related articles for article (PubMed ID: 37771595)
1. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels.
Golomingi M; Kohler J; Lamers C; Pouw RB; Ricklin D; Dobó J; Gál P; Pál G; Kiss B; Dopler A; Schmidt CQ; Hardy ET; Lam W; Schroeder V
Front Immunol; 2023; 14():1226832. PubMed ID: 37771595
[TBL] [Abstract][Full Text] [Related]
2. Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model.
Golomingi M; Kohler J; Jenny L; Hardy ET; Dobó J; Gál P; Pál G; Kiss B; Lam WA; Schroeder V
Front Immunol; 2022; 13():948190. PubMed ID: 36032172
[TBL] [Abstract][Full Text] [Related]
3. MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model.
Jenny L; Dobó J; Gál P; Pál G; Lam WA; Schroeder V
PLoS One; 2018; 13(1):e0191292. PubMed ID: 29324883
[TBL] [Abstract][Full Text] [Related]
4. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation.
Kozarcanin H; Lood C; Munthe-Fog L; Sandholm K; Hamad OA; Bengtsson AA; Skjoedt MO; Huber-Lang M; Garred P; Ekdahl KN; Nilsson B
J Thromb Haemost; 2016 Mar; 14(3):531-45. PubMed ID: 26614707
[TBL] [Abstract][Full Text] [Related]
5. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
6. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/
Machida T; Sakamoto N; Ishida Y; Takahashi M; Fujita T; Sekine H
Front Immunol; 2018; 9():1191. PubMed ID: 29892304
[TBL] [Abstract][Full Text] [Related]
7. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development.
Subramaniam S; Jurk K; Hobohm L; Jäckel S; Saffarzadeh M; Schwierczek K; Wenzel P; Langer F; Reinhardt C; Ruf W
Blood; 2017 Apr; 129(16):2291-2302. PubMed ID: 28223279
[TBL] [Abstract][Full Text] [Related]
8. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.
Hess K; Ajjan R; Phoenix F; Dobó J; Gál P; Schroeder V
PLoS One; 2012; 7(4):e35690. PubMed ID: 22536427
[TBL] [Abstract][Full Text] [Related]
9. Distinction of early complement classical and lectin pathway activation
Hurler L; Toonen EJM; Kajdácsi E; van Bree B; Brandwijk RJMGE; de Bruin W; Lyons PA; Bergamaschi L; ; Sinkovits G; Cervenak L; Würzner R; Prohászka Z
Front Immunol; 2022; 13():1039765. PubMed ID: 36420270
[TBL] [Abstract][Full Text] [Related]
10. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.
Møller-Kristensen M; Thiel S; Sjöholm A; Matsushita M; Jensenius JC
Int Immunol; 2007 Feb; 19(2):141-9. PubMed ID: 17182967
[TBL] [Abstract][Full Text] [Related]
11. MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway.
Vorup-Jensen T; Jensenius JC; Thiel S
Immunobiology; 1998 Aug; 199(2):348-57. PubMed ID: 9777418
[TBL] [Abstract][Full Text] [Related]
12. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2.
Héja D; Kocsis A; Dobó J; Szilágyi K; Szász R; Závodszky P; Pál G; Gál P
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10498-503. PubMed ID: 22691502
[TBL] [Abstract][Full Text] [Related]
13. Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives.
Mollnes TE; Storm BS; Brekke OL; Nilsson PH; Lambris JD
Semin Immunol; 2022 Jan; 59():101604. PubMed ID: 35570131
[TBL] [Abstract][Full Text] [Related]
14. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.
Gulla KC; Gupta K; Krarup A; Gal P; Schwaeble WJ; Sim RB; O'Connor CD; Hajela K
Immunology; 2010 Apr; 129(4):482-95. PubMed ID: 20002787
[TBL] [Abstract][Full Text] [Related]
15. The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while α2-macroglobulin is not.
Paréj K; Dobó J; Závodszky P; Gál P
Mol Immunol; 2013 Jul; 54(3-4):415-22. PubMed ID: 23399388
[TBL] [Abstract][Full Text] [Related]
16. PO-20 - Crosstalk between the lectin pathway and haemostasis in patients with pulmonary cancer.
Larsen JB; Christensen TD; Hvas CL; Hvas AM
Thromb Res; 2016 Apr; 140 Suppl 1():S183. PubMed ID: 27161707
[TBL] [Abstract][Full Text] [Related]
17. Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.
Sonnentag SJ; Dopler A; Kleiner K; Garg BK; Mannes M; Späth N; Akilah A; Höchsmann B; Schrezenmeier H; Anliker M; Boyanapalli R; Huber-Lang M; Schmidt CQ
J Biol Chem; 2024 Apr; 300(4):105784. PubMed ID: 38401844
[TBL] [Abstract][Full Text] [Related]
18. TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2.
Keizer MP; Pouw RB; Kamp AM; Patiwael S; Marsman G; Hart MH; Zeerleder S; Kuijpers TW; Wouters D
Eur J Immunol; 2015 Feb; 45(2):544-50. PubMed ID: 25359215
[TBL] [Abstract][Full Text] [Related]
19. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
Wallis R; Dodds AW; Mitchell DA; Sim RB; Reid KB; Schwaeble WJ
J Biol Chem; 2007 Mar; 282(11):7844-51. PubMed ID: 17204478
[TBL] [Abstract][Full Text] [Related]
20. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
